Published online Sep 26, 2020. doi: 10.12998/wjcc.v8.i18.4010
Peer-review started: June 5, 2020
First decision: July 25, 2020
Revised: August 12, 2020
Accepted: August 22, 2020
Article in press: August 22, 2020
Published online: September 26, 2020
Processing time: 108 Days and 16.7 Hours
Patients with diabetes mellitus may develop skeletal complications including osteopenia, osteoporosis and even fracture. Although metformin is used as an antidiabetic rather than an antiosteoporotic medicine, it is essential to examine the effects of metformin on bone metabolism because it is a widely used medication to treat diabetes in this population.
By comparing different doses of metformin on bone metabolism and bone mineral density (BMD) in patients with type 2 diabetes, the optimal dose of metformin will be estimated to achieve the benefits of bone protection beyond glycemic control.
The aim of this study is to compare the effects of a high dose vs low dose of metformin on BMD and bone metabolism in patients with type 2 diabetes mellitus.
One hundred and twenty patients with type 2 diabetes were enrolled in the study. They were assigned to a high dose metformin group (2 g daily) and a low dose metformin group (1 g daily) with 60 patients in each group for 12 wk. Changes in BMD and bone metabolism as well as the efficacy of the treatment were compared between the two groups before and after treatment.
The results showed that there was no significant difference in the treatment efficacy between the two treatment groups. After the treatment, levels of BMD and bone metabolic markers were improved. To be specific, levels of BMD and 25-hydroxyvitamin D were higher in the high dose metformin group than in the low dose metformin group. However, levels of N-terminal midfragment and β-isomerized C-terminal telopeptides were lower in the high dose metformin group than in the low dose metformin group.
A high dosage of metformin can help to improve osteoporosis as well as control blood glucose in elderly male patients with type 2 diabetes mellitus.
The effects of metformin on BMD and bone metabolism should be further evaluated in long-term observational studies with large sample sizes.